The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awarded the third annual Healey Center International Prize for Innovation in ALS to the team responsible for the conception, construction, dissemination, and maintenance of the PRO-ACT database that has enabled the new field of ALS predictive analytics.
A normally fractious U.S. House of Representatives came together to provide money for more research and better access to experimental treatments for people afflicted with ALS.
Everyone will be able to unite safely and social distance while walking a couple of laps around the lovely Tom Brown Park. To participate, register a team by contacting Michelle Decker at mdecker@alsafl.org or 888.257.1717 x130.
Study flips belief that disease starts in the spinal cord
‘We need to repair brain motor neurons for effective strategies’
Scientists identify first gene target to revitalize brain motor neuron
ZZ Biotech, a clinical stage biopharmaceutical company developing the experimental drug 3K3A-APC for some of the biggest unmet needs in stroke, neurodegenerative disease and chronic wound healing, today announced that the first patients have been dosed in a Phase 2 clinical trial evaluating 3K3A-APC for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Proceeds from the online auction that runs through Tuesday will benefit the Peter Frates Family Foundation, which assists ALS patients and their families with the cost of home health care, according to a spokesperson for auctioneer KBK Sports.